Despite the introduction of various modern and minimally invasive glaucoma procedures, trabeculectomy is still considered to be the most effective treatment for glaucoma and the cornerstone of management for this potentially blinding condition. 1 It is a rather unique surgical procedure in medicine, because prevention of wound healing is crucial for surgical success. 2 Indeed, progressive fibroblast proliferation and collagen deposition at the site of the filtration bleb, and development of fibrosis in the conjunctiva and episclera are the most common causes of trabeculectomy failure. 2, 3 Thus targeting the healing process is highly important for success in trabeculectomy. In current practice, perioperative anti-mitotic agents such as mitomycin C (MMC) and 5-fluorouracil (5-FU) are administered to improve surgical success; 4 however, these agents carry a significant risk of vision-threatening complications such as toxicity to the corneal endothelium, scleral thinning, hypotony, bleb leakage, blebitis and endophthalmitis. 1, [5] [6] [7] Because of these, there is a need for more targeted and effective antiscarring interventions.
Wound healing involves a complex interaction between humoral and cellular responses, and occurs through four interconnected processes: clot formation, angiogenesis, inflammation and collagen deposition. Among these components, angiogenesis plays a key role because it provides the substrate for wound healing at the site of injury. 8 Vascular endothelial growth factor (VEGF), as an endothelial and permeability factor, has a prominent role in physiological and pathological angiogenesis. However, beside angiogenesis it can stimulate many non-vascular cells, such as Tenon's fibroblasts. 9 It is hypothesized that VEGF may be a survival factor for certain non-angiogenic blood vessels in adults. 10 VEGF has three high affinity receptors, among which, VEGF-R2 mediates most of its biologically relevant responses, including cell migration and proliferation. 11 Various isoforms of VEGF, such as VEGF 121 , VEGF 165 and VEGF 189 , result from alternate splicing of a single VEGFgene; these isoforms differ in the number of amino acids, molecular weight, and co-receptor binding properties. 12, 13 While various isoforms have the same affinity for VEGF-R2 receptor, 14, 15 they significantly differ in their affinity to VEGF co-receptors, such as neurophilin-1 (NRP-1) and heparin sulphate proteoglycans (HSPGs). Because of this variation, differential tissue effects have been demonstrated for various isoforms: VEGF 165 and VEGF 121 predominantly affect blood vessel growth and angiogenesis, while VEGF 189 has a more prominent role in fibrosis and wound healing processes. 16 As mentioned above, VEGF has potential direct and indirect roles in wound healing and there are reports of delayed wound healing and an increased incidence of wound dehiscence following systemic use of bevacizumab. 17, 18 Several investigators demonstrated that VEGF is present in aqueous humor samples of glaucoma patients undergoing filtering surgery and its receptors are expressed on Tenon's fibroblasts. 9, 19, 20 At the filtering site, VEGF could modify fibroblast activity and stimulate collagen cross-linking and contraction, resulting in scar formation. 9 Moreover, higher VEGF levels in Tenon's tissue preoperatively are associated with a worse outcome following trabeculectomy surgery. 20 Based on these evidences, targeting VEGF to modulate wound healing following trabeculectomy surgery has been a hot topic of research over the past few years. Several investigators have tried various anti-VEGF drugs and different administration routes to increase the success of trabeculectomy with variable results (Table 1) . 21 Table 1 . Summary of studies on the use of anti-VEGF agents for filtering surgery* for treatment of colorectal and breast cancers and is used off-label in many ocular conditions. There are different routes of bevacizumab administration with potential ocular effects, including subconjunctival injection, intravitreal injection, and topical administration in the form of eye drops 38 or soaked sponges. While intravitreal administration is the most effective route for intraocular tissue, the longest biologic half-life is achieved by subconjunctival injection because of bevacizumab binding to scleral matrix and its storage-effect. 39 With respect to filtering surgery, subconjunctival injection seems to be the most appropriate route.
When using bevacizumab in filtering surgery, one should consider that in several studies it has been shown that there is more bleb encapsulation with bevacizumab as compared to MMC and several studies suggest that MMC is more effective than bevacizumab in achieving a diffuse filtering bleb in primary trabeculectomy. 33, 35 There are several explanations for this phenomenon. First, the role of antiproliferative agents on prevention of bleb-encapsulation is not proven and controversial. 2, [40] [41] [42] Moreover, bevacizumab may have limited sensitivity to different subtypes of fibroblasts active in encapsulation or it could have insufficient effect on inflammatory mediators. Direct toxicity of MMC to the ciliary epithelium and decreased aqueous humor secretion is another explanation.
Considering bevacizumab as an adjuvant for trabeculectomy, one should also consider the contraindications for bevacizumab use, including pregnancy, breast feeding, uncontrolled systemic hypertension, and cerebrovascular accidents or transient ischemic attacks one month prior to injection. Moreover, complications such as conjunctival necrosis have been reported following subconjunctival bevacizumab 34 and intravitreal ranibizumab 43 injection. In summary, while anti-VEGF agents seem to offer valuable augmentation of trabeculectomy surgery, sufficient evidence on their long-term safety and efficacy are lacking. More specific anti-VEGF agents, perhaps targeting VEGF 189 could improve their potency and decrease the complications. In addition, increasing their duration of effect would be necessary for longterm success of filtering surgery.
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